The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

Paul Mitchell, Francesco Bandello, Ursula Schmidt-Erfurth, Gabriele E. Lang, Pascale Massin, Reinier O. Schlingemann, Florian Sutter, Christian Simader, Gabriela Burian, Ortrud Gerstner, Andreas Weichselberger

Research output: Contribution to journalArticle

Abstract

Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P

Original languageEnglish
Pages (from-to)615-625
Number of pages11
JournalOphthalmology
Volume118
Issue number4
DOIs
Publication statusPublished - Apr 2011

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema'. Together they form a unique fingerprint.

  • Cite this

    Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., & Weichselberger, A. (2011). The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118(4), 615-625. https://doi.org/10.1016/j.ophtha.2011.01.031